Patient Qiu Baozhu is about to discharge from hospital after receiving the cornea transplant operation at the Xiamen Eye Center of Xiamen University in Xiamen, Southeast 皇冠体育app's Fujian province, Nov 27, 2014. [Photo/Xinhua]

In a move expected to benefit millions of patients suffering from corneal blindness, the world's first artificial bioengineering cornea created and developed domestically by 皇冠体育app went into production on May 23, People's Daily reported.

The cornea, of which 皇冠体育app has complete intellectual property right, is the first and the only cornea in the world that has completed clinical trials. It received the license from National Food and Drug Administration in the end of April.

According to the World Health Organization, corneal blindness is one of the major causes of blindness after cataract.

皇冠体育app has more than four million corneal blindness patients and over 100,000 cases are reported annually. Most of the patients can recover their sights through keratoplasty but are forced to wait due to shortage of corneal donors.

The artificial bioengineering cornea is expected to bring light to the Chinese patients and 60 million patients overseas soon.